DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2010. Total revenues were $8.1 million for the three months ended September 30, 2010 compared to $8.4 million for the three...(read more)
Durect Corporation (DRRX) focuses on the development and commercialization of pharmaceutical systems that enhance treatment capabilities associated with chronic pain, cardiovascular diseases, and central nervous system disorders. The company uses six technology platforms:
SABER: A controlled-release technology that utilizes an injectable biodegradable gel for administration of small peptides, proteins, or small molecules.